Travere Therapeutics, Inc.

NasdaqGM:TVTX Stock Report

Market Cap: US$1.7b

Travere Therapeutics Valuation

Is TVTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TVTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TVTX ($19.22) is trading below our estimate of fair value ($113.59)

Significantly Below Fair Value: TVTX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TVTX?

Key metric: As TVTX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TVTX. This is calculated by dividing TVTX's market cap by their current revenue.
What is TVTX's PS Ratio?
PS Ratio8.2x
SalesUS$203.45m
Market CapUS$1.69b

Price to Sales Ratio vs Peers

How does TVTX's PS Ratio compare to its peers?

The above table shows the PS ratio for TVTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.6x
CDNA CareDx
4.3x12.3%US$1.3b
NTLA Intellia Therapeutics
34.8x67.2%US$1.4b
MYGN Myriad Genetics
1.7x7.2%US$1.5b
NVAX Novavax
1.6x-10.2%US$1.3b
TVTX Travere Therapeutics
8.2x31.7%US$1.7b

Price-To-Sales vs Peers: TVTX is good value based on its Price-To-Sales Ratio (8.2x) compared to the peer average (10.6x).


Price to Sales Ratio vs Industry

How does TVTX's PS Ratio compare vs other companies in the US Biotechs Industry?

143 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.5x2.3%US$147.46b
GILD Gilead Sciences
4.1x2.4%US$116.39b
BIIB Biogen
2.4x1.3%US$23.21b
MRNA Moderna
3.4x6.6%US$16.52b
TVTX 8.2xIndustry Avg. 10.9xNo. of Companies143PS020406080100+
143 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TVTX is good value based on its Price-To-Sales Ratio (8.2x) compared to the US Biotechs industry average (11.2x).


Price to Sales Ratio vs Fair Ratio

What is TVTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TVTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.2x
Fair PS Ratio5.8x

Price-To-Sales vs Fair Ratio: TVTX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the estimated Fair Price-To-Sales Ratio (5.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TVTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.22
US$27.40
+42.6%
30.1%US$42.00US$15.00n/a15
Nov ’25US$17.57
US$26.38
+50.1%
34.1%US$43.00US$12.00n/a16
Oct ’25US$13.99
US$17.00
+21.5%
26.1%US$23.00US$9.00n/a14
Sep ’25US$9.47
US$15.36
+62.2%
23.2%US$20.00US$9.00n/a14
Aug ’25US$9.24
US$14.86
+60.8%
24.5%US$20.00US$9.00n/a14
Jul ’25US$8.28
US$14.86
+79.4%
24.5%US$20.00US$9.00n/a14
Jun ’25US$7.42
US$14.86
+100.2%
24.5%US$20.00US$9.00n/a14
May ’25US$6.00
US$14.79
+146.4%
25.3%US$21.00US$9.00n/a14
Apr ’25US$7.31
US$14.80
+102.5%
23.9%US$21.00US$9.00n/a15
Mar ’25US$7.87
US$14.80
+88.1%
23.9%US$21.00US$9.00n/a15
Feb ’25US$8.60
US$14.73
+71.3%
29.5%US$23.00US$8.00n/a15
Jan ’25US$8.99
US$14.40
+60.2%
32.8%US$23.00US$8.00n/a15
Dec ’24US$6.42
US$14.07
+119.1%
34.4%US$23.00US$7.00US$18.8115
Nov ’24US$6.72
US$15.43
+129.6%
34.4%US$25.00US$8.00US$17.5714
Oct ’24US$8.94
US$18.64
+108.5%
49.2%US$41.00US$8.00US$13.9914
Sep ’24US$14.87
US$26.93
+81.1%
27.5%US$41.00US$15.00US$9.4714
Aug ’24US$16.72
US$28.00
+67.5%
26.9%US$41.00US$15.00US$9.2414
Jul ’24US$15.36
US$28.29
+84.2%
26.4%US$39.00US$15.00US$8.2814
Jun ’24US$18.20
US$28.77
+58.1%
26.2%US$39.00US$15.00US$7.4213
May ’24US$22.61
US$35.08
+55.2%
26.6%US$52.00US$17.00US$6.0012
Apr ’24US$22.49
US$34.92
+55.3%
26.3%US$52.00US$17.00US$7.3112
Mar ’24US$21.74
US$35.62
+63.8%
25.7%US$52.00US$17.00US$7.8713
Feb ’24US$22.09
US$32.92
+49.0%
24.3%US$44.00US$17.00US$8.6012
Jan ’24US$21.03
US$31.83
+51.4%
23.6%US$44.00US$17.00US$8.9912
Dec ’23US$19.54
US$33.20
+69.9%
22.2%US$44.00US$17.00US$6.4210

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies